title: Combined trans- and periurethral injections of bulking agents for the treatment of intrinsic sphincter deficiency.
abstract: The purpose of this study was to compare Contigen combined with Durasphere to Contigen injections alone for the treatment of stress urinary incontinence (SUI) with intrinsic sphincter deficiency (ISD). Subjective and objective incontinence outcomes were compared at 2 weeks and 6 months. We compared rates of urinary retention and future incontinence surgery between groups. Thirty-three women underwent combined injections, and 51 underwent Contigen injections. Two weeks postoperatively, more women in the combined group were cured (72.7 vs. 39.2%, P = 0.003), but this difference diminished at 6 months (33.3 vs. 29.4%, P = 0.70). Retention was more common in the combined group (P = 0.002, odds ratio [OR] = 0.062 [95% confidence interval (CI) = 0.007, 0.52]). Twenty-three women in the Contigen and ten in the combined group underwent subsequent incontinence surgery (P = 0.17, OR = 2.03 [95% CI = 0.80, 5.1]). Combining Contigen and Durasphere injections to treat SUI with ISD does not improve outcomes compared to Contigen injections alone.
authors.affiliation: Urogynecology and Reconstructive Pelvic Surgery, Stanford University School of Medicine, 300 Pasteur Drive, Room HH333, Stanford, CA 94305, USA. esokol@stanford.edu
authors.forename: Eric R
authors.initials: ER
authors.lastname: Sokol
authors.forename: Vivian C
authors.initials: VC
authors.lastname: Aguilar
authors.forename: Vivian W
authors.initials: VW
authors.lastname: Sung
authors.forename: Deborah L
authors.initials: DL
authors.lastname: Myers
mesh_terms: D000368:Aged; D001672:Biocompatible Materials / Q000008:administration & dosage*; D003094:Collagen / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D005936:Glucans / Q000008:administration & dosage*; D006801:Humans; D007267:Injections; D019736:Prostheses and Implants; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014521:Urethra; D014550:Urinary Incontinence, Stress / Q000188:drug therapy* / Q000503:physiopathology; D014563:Urodynamics / Q000502:physiology; D015040:Zirconium / Q000008:administration & dosage*
chemical_list: D001672:Biocompatible Materials; D005936:Glucans; C431745:durasphere; C048470:glutaraldehyde-cross-linked collagen; D003094:Collagen; D015040:Zirconium